RxDoctor Payments Data

Vicky St John, APRN

Family · Jasper, TXNPI 1033580394

Payments from drug & device makers

$298in general payments, 2019–2025

Across 16 payments — averaging $18.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$90
  • Novo Nordisk$37
  • Hologic Sales And Service, LLC$36
  • Tactile Systems Technology Inc$35
  • Organon$22
  • Merck$19
  • plus $59 from 4 others

What the payments were for

  • Food & beverage$298100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$298 in reported general payments places this provider in the 45th percentile of 15,456 family providers in Texas.

See all family providers in Texas

Medicare billing

Part B allowed, 2024
$1,883
Medicare patients
18
Services billed
18

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban308$101,099
JanuviaSitagliptin Phosphate139$43,435
FarxigaDapagliflozin Propanediol113$39,601
TrulicityDulaglutide37$36,698
JardianceEmpagliflozin69$30,179
XareltoRivaroxaban98$27,740
OzempicSemaglutide20$19,451
RexultiBrexpiprazole25$18,240
RybelsusSemaglutide12$12,457
MyrbetriqMirabegron47$10,848
EntrestoSacubitril/Valsartan29$9,015
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr17$8,966
Divalproex Sodium201$7,556
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog36$6,958
NamzaricMemantine Hcl/Donepezil Hcl22$6,253

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia, Janumet$19$49,301176 claims
Novo NordiskOzempic, Rybelsus$37$31,90832 claims
AbbVieNamzaric$90$6,25322 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 15,456 family providers in Texas.

Other family in Jasper

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →